论文部分内容阅读
目的:观察氟桂嗪与尼莫地平防治偏头痛的疗效,并探讨其作用机制。方法:2001/2004,济南长城医院神经内科,山东大学齐鲁医院神经内科,泰山医学院脑血管病研究所,梁山县人民医院神经内科,山东省警官医院神经内科,东明县中医院神经内科,山东省千佛山医院神经内科,济南市立四院神经内科,潍坊市人民医院神经内科,山东省立医院神经内科。选择 220例偏头痛患者,随机分为两组,氟桂嗪治疗组与尼莫地平治疗组,每组各 110例。采用视觉线性模拟量表 visuallinear (analogue scale,VAS)、文字分级量表 verbalrating scale,VRS)及疗程中 (非疼痛时间判断疗效。采用放免法测定血浆 β-内啡肽、神经降压素、内皮素、环磷酸腺苷与环磷酸鸟苷水平变化。结果:纳入统计分析 200例,氟桂嗪治疗组与尼莫地平治疗组各 100例。氟桂嗪组治疗后 VAS(3.6±1.7)cm ,较治疗前(7.3±2.6)cm 显著降低(P<0.01),VRS( 2.0±0.4)分,较治疗前 3.9±0.7)分显著降低(P (<0.01),非疼痛时间(15±4)d,较治疗前(7±2)d 显著增多(P <0.01);尼莫地平组治疗后 VAS(5.2±1.9)cm,较治疗前 7.2±2.2)cm 显著 (降低 P <0.05),VRS(2.9±0.
Objective: To observe the efficacy of flunarizine and nimodipine in the prevention and treatment of migraine and to explore its mechanism. Methods: 2001/2004, Department of Neurology, Jinan Great Wall Hospital, Department of Neurology, Qilu Hospital of Shandong University, Institute of Cerebrovascular Diseases of Taishan Medical College, Department of Neurology, Liangshan County People’s Hospital, Department of Neurology, Shandong Provincial Police Hospital, Department of Neurology, Dongming Hospital of Traditional Chinese Medicine, Department of Neurology, Qianfoshan Hospital, Department of Neurology, Fourth Hospital of Jinan, Department of Neurology, Weifang People’s Hospital, and Department of Neurology, Shandong Provincial Hospital. 220 migraineurs were selected and randomly divided into two groups: flunarizine treatment group and nimodipine treatment group, with 110 cases in each group. The visual analog scale scale (VAS), verbal scale scale (VRS) and course of treatment (non-pain time) were used to evaluate the curative effect.Plasma β-endorphin, neurotensin, endothelium , Cyclic adenosine monophosphate and cyclic guanosine monophosphate were detected.Results: 200 cases were included in the statistical analysis, 100 cases in the flunarizine treatment group and nimodipine treatment group respectively.VAS (3.6 ± 1.7) cm (P <0.01), non-pain time (15 ± 4) was significantly lower than that before treatment (7.3 ± 2.6) cm (P <0.01) ) d was significantly higher than that before treatment (7 ± 2) d (P <0.01); VAS after Nimodipine treatment (5.2 ± 1.9) cm was significantly (P <0.05) lower than that before treatment VRS (2.9 ± 0.